This episode contains part 2 of our conversation with Michael Macklin, MD, PharmD, Assistant Professor of Medicine at the University of Chicago, about the Cytokine Crushers region of RheumMadness 2025.

In this episode, we focus specifically on the TYK2 in SLE and Oral Anti-IL23 teams. 

Links to the Cytokine Crushers Scouting Reports:

• Oral anti-IL23, by collaborating Chicago area rheumatology fellowship programs (Loyola, Northwestern, and the University of Chicago)
• Long-term outcomes of anifrolumab in SLE, by the Medical University of South Carolina (MUSC) Adult Rheumatology Fellowship
• TYK2 inhibitor in SLE, by the University of North Carolina (UNC) Adult Rheumatology Fellowship

Links to theMednet.org Q&As about this region:

• What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for management of psoriasis/PsA?
• How will you utilize newly FDA approved anifrolumab for SLE in your practice?
• What is your experience with using oral deucravicitinib for conditions such as recalcitrant facial discoid lupus or recalcitrant lichen planus?

To learn more about RheumMadness:
https://sites.duke.edu/rheummadness/

Subscribe to our newsletter:
https://lists.duke.edu/sympa/subscribe/rheummadness

Find us on social media:
Bluesky: @rheummadness.bsky.social
Instagram: https://www.instagram.com/rheummadness/
X: Follow #RheumMadness


Intro/outro music: Cheery Monday by Kevin MacLeod
Link: https://incompetech.filmmusic.io/song/3495-cheery-monday
License: http://creativecommons.org/licenses/by/4.0/

In this episode, we are joined by Michael Macklin, MD, PharmD, Assistant Professor of Medicine at the University of Chicago, to discuss the teams in the Cytokine Crushers region of RheumMadness 2025, the Innovation Invitational.

This is part 1 of the conversation, where we go in depth about the long-term outcomes of anifrolumab in SLE study and give a primer about type 1/2 cytokines so you're ready to dig into the TYK2 in SLE and Oral Anti-IL23 studies.

Join us again next week for part 2 of this discussion to learn more about this region.

Links to the Cytokine Crushers Scouting Reports:

• Oral anti-IL23, by collaborating Chicago area rheumatology fellowship programs (Loyola, Northwestern, and the University of Chicago)
• Long-term outcomes of anifrolumab in SLE, by the Medical University of South Carolina (MUSC) Adult Rheumatology Fellowship
• TYK2 inhibitor in SLE, by the University of North Carolina (UNC) Adult Rheumatology Fellowship

Links to old scouting reports and other studies referenced in this podcast:

• TULIP 1/2 scouting report from RheumMadness 2021
• LLDAS scouting report from RheumMadness 2024
• Morand EF, Abreu G, Furie RA, Golder V, Tummala R. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Ann Rheum Dis. 2023 May;82(5):639-645. doi: 10.1136/ard-2022-222748. Epub 2023 Jan 23. Erratum in: Ann Rheum Dis. 2024 Apr 11;83(5):e12. doi: 10.1136/ard-2022-222748corr1. PMID: 36690388; PMCID: PMC10176410.
• Tanaka Y. Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice. RMD Open. 2023 Aug;9(3):e003270. doi: 10.1136/rmdopen-2023-003270. Erratum in: RMD Open. 2024 Apr 4;10(2):e003270corr1. doi: 10.1136/rmdopen-2023-003270corr1. PMID: 37597847; PMCID: PMC10441065.
• ORAL Surveillance scouting report from RheumMadness 2024

To learn more about RheumMadness:
https://sites.duke.edu/rheummadness/

Subscribe to our newsletter:
https://lists.duke.edu/sympa/subscribe/rheummadness

Find us on social media:
Bluesky: @rheummadness.bsky.social
Instagram: https://www.instagram.com/rheummadness/
X: Follow #RheumMadness


Intro/outro music: Cheery Monday by Kevin MacLeod
Link: https://incompetech.filmmusic.io/song/3495-cheery-monday
License: http://creativecommons.org/licenses/by/4.0/

In this episode, we present the second part of our conversation with the authors of the scouting reports for the teams in the T'd Up T-cells region of RheumMadness 2025: the Innovation Invitational.  Plus, we highlight Q&As from theMednet.org about the T'd Up T-Cells teams AND record an interview with Dr. Bill St. Clair, the first author of the phase 2 dazodalibep study.  It's a long episode because there's so much content!

Links to the Q&As from theMednet.org discussed in this episode:

• What is your approach to managing sicca symptoms in patients not responding or not tolerating conservative measures, pilocarpine, and cevimeline?
• What is your approach to immunomodulatory treatment in patients with Sjogren’s syndrome who have active serologies (i.e. elevated ESR, hypergammaglobulinemia, hypocomplementemia) but minimal symptoms?
• What is your approach to monitoring patients referred for high titer +RF and +CCP but without active symptoms of inflammatory arthritis?
• What factors drive you to prioritize T vs B cell inhibition when choosing therapies for patients with refractory SLE?

To learn more about RheumMadness:
https://sites.duke.edu/rheummadness/

Subscribe to our newsletter:
https://lists.duke.edu/sympa/subscribe/rheummadness

Find us on social media:
Bluesky: @rheummadness.bsky.social
Instagram: https://www.instagram.com/rheummadness/
X: Follow #RheumMadness


Intro/outro music: Cheery Monday by Kevin MacLeod
Link: https://incompetech.filmmusic.io/song/3495-cheery-monday
License: http://creativecommons.org/licenses/by/4.0/

In this episode, we dive in to the T'd Up T-cells region of RheumMadness 2025: the Innovation Invitational.  This is the first of a two-part conversation with the authors of the scouting reports for the teams in this region.  Check back next week to hear the rest of the conversation!

To find the scouting reports and base articles discussed in this episode, head over to the scouting reports page of our website here:
https://sites.duke.edu/rheummadness/bracket-and-scouting-reports/

To learn more about RheumMadness:
https://sites.duke.edu/rheummadness/

Find us on social media:
Bluesky: @rheummadness.bsky.social
Instagram: https://www.instagram.com/rheummadness/
X: Follow #RheumMadness


Intro/outro music: Cheery Monday by Kevin MacLeod
Link: https://incompetech.filmmusic.io/song/3495-cheery-monday
License: http://creativecommons.org/licenses/by/4.0/

Welcome back to RheumMadness, the place for everyone who is crazy about rheumatology to connect, collaborate, compete, and learn together.

The podcast took a hiatus in 2024 (hence why there are no episodes labeled season 4), but we we are thrilled to announce that the podcast is back for 2025 and beyond.  

In this episode, we explain some changes to the RheumMadness format and get you ready to experience everything this season has to offer.

Find out more on the RheumMadness website:
https://sites.duke.edu/rheummadness/

Find us on social media:
Bluesky: @rheummadness.bsky.social
Instagram: https://www.instagram.com/rheummadness/
X: Follow #RheumMadness


Intro/outro music: Cheery Monday by Kevin MacLeod
Link: https://incompetech.filmmusic.io/song/3495-cheery-monday
License: http://creativecommons.org/licenses/by/4.0/

In this episode, we are joined by two Blue Ribbon Panel members (Dr. Julie Paik and Dr. Angus Worthing) to recap the results of RheumMadness 2023. Plus, we hear from Dr. Nina Couette to review all the RheumMadness-related content on theMednet.org.

Find out more on the RheumMadness website:
https://sites.duke.edu/rheummadness/


Intro/outro music: Cheery Monday by Kevin MacLeod
Link: https://incompetech.filmmusic.io/song/3495-cheery-monday
License: http://creativecommons.org/licenses/by/4.0/

For this episode, we invited anyone who wanted to join us for a live group discussion about the All Star Season.  The result?  Our first international guest on the podcast, two more fellow scouting report authors, and a ton of fun.  Plus, hear Guy Katz make his picks (so you know who not to pick in the tournament), and hear a rundown of what we think the Blue Ribbon Panel might do. 

RheumMadness website: https://sites.duke.edu/rheummadness/


Intro/outro music:
Cheery Monday by Kevin MacLeod
Link: https://incompetech.filmmusic.io/song/3495-cheery-monday
License: http://creativecommons.org/licenses/by/4.0/

In this episode, we discuss the right side of the bracket for RheumMadness 2023 with the scouting report authors. (Part 2 of 2)

RheumMadness website: https://sites.duke.edu/rheummadness/


Intro/outro music:
Cheery Monday by Kevin MacLeod
Link: https://incompetech.filmmusic.io/song/3495-cheery-monday
License: http://creativecommons.org/licenses/by/4.0/

In this episode, we discuss the right side of the bracket for RheumMadness 2023 with the scouting report authors. (Part 1 of 2)

RheumMadness website: https://sites.duke.edu/rheummadness/


Intro/outro music:
Cheery Monday by Kevin MacLeod
Link: https://incompetech.filmmusic.io/song/3495-cheery-monday
License: http://creativecommons.org/licenses/by/4.0/

In this episode, we discuss the left side of the bracket for RheumMadness 2023 with the scouting report authors. (Part 2 of 2)

RheumMadness website: https://sites.duke.edu/rheummadness/


Intro/outro music:
Cheery Monday by Kevin MacLeod
Link: https://incompetech.filmmusic.io/song/3495-cheery-monday
License: http://creativecommons.org/licenses/by/4.0/